This is a parallel, Phase 2/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.

Participation to the study consists of 3 periods:

Screening period of up to 4 weeks
Randomized intervention period of approximately 48 weeks
Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.